Helix BioMedix, Inc. Announces U.S. Patent Issuance for Novel Class of Antimicrobial

BOTHELL, Wash.--(BUSINESS WIRE)--Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced that it has been issued U.S. Patent number 7,407,940 by the United States Patent and Trademark Office, which includes the company’s lead pre-clinical lipohexapeptide candidates.

Back to news